Literature DB >> 24581450

Why have clinical trials in sepsis failed?

John C Marshall1.   

Abstract

The systemic inflammatory response is biologically complex, redundant, and activated by both infectious and noninfectious triggers. Its manipulation can cause both benefit and harm. More than 100 randomized clinical trials have tested the hypothesis that modulating the septic response to infection can improve survival. With one short-lived exception, none of these has resulted in new treatments. The current challenge for sepsis research lies in a failure of concept and reluctance to abandon a demonstrably ineffectual research model. Future success will necessitate large studies of clinical and biochemical epidemiology to understand the course of illness, better integration of basic and clinical science, and the creation of stratification systems to target treatment towards those who are most likely to benefit.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  adjuvant therapy; biologic response modifier; clinical trials; innate immunity; intensive care; sepsis; septic shock; staging

Mesh:

Substances:

Year:  2014        PMID: 24581450     DOI: 10.1016/j.molmed.2014.01.007

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  231 in total

Review 1.  Immune therapy in sepsis: Are we ready to try again?

Authors:  Roger Davies; Kieran O'Dea; Anthony Gordon
Journal:  J Intensive Care Soc       Date:  2018-04-04

Review 2.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

3.  Inducible Nitric Oxide Synthase in Circulating Microvesicles: Discovery, Evolution, and Evidence as a Novel Biomarker and the Probable Causative Agent for Sepsis.

Authors:  Robert J Webber; Richard M Sweet; Douglas S Webber
Journal:  J Appl Lab Med       Date:  2019-01

4.  Mechanistic insights into cell-free hemoglobin-induced injury during septic shock.

Authors:  Jeffrey Wang; Willard N Applefeld; Junfeng Sun; Steve B Solomon; Jing Feng; Zoe G Couse; Thomas F Risoleo; Robert L Danner; Jesús Tejero; Juan Lertora; Elmira Alipour; Swati Basu; Vandana Sachdev; Daniel B Kim-Shapiro; Mark T Gladwin; Harvey G Klein; Charles Natanson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-05-14       Impact factor: 4.733

5.  The uncovering of ESE-1 in human neutrophils: implication of its role in neutrophil function and survival.

Authors:  C M Lee; S Gupta; J Parodo; J Wu; J C Marshall; J Hu
Journal:  Genes Immun       Date:  2015-04-23       Impact factor: 2.676

6.  Genomic responses in mouse models greatly mimic human inflammatory diseases.

Authors:  Keizo Takao; Tsuyoshi Miyakawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 7.  The immunopathology of sepsis and potential therapeutic targets.

Authors:  Tom van der Poll; Frank L van de Veerdonk; Brendon P Scicluna; Mihai G Netea
Journal:  Nat Rev Immunol       Date:  2017-04-24       Impact factor: 53.106

8.  Juvenile OLFM4-null mice are protected from sepsis.

Authors:  Julie E Stark; Amy M Opoka; Jaya Mallela; Prasad Devarajan; Qing Ma; Nick C Levinsky; Keith F Stringer; Hector R Wong; Matthew N Alder
Journal:  Am J Physiol Renal Physiol       Date:  2020-02-18

9.  Plasma Proteome Signature of Sepsis: a Functionally Connected Protein Network.

Authors:  Genaro Pimienta; Douglas M Heithoff; Alexandre Rosa-Campos; Minerva Tran; Jeffrey D Esko; Michael J Mahan; Jamey D Marth; Jeffrey W Smith
Journal:  Proteomics       Date:  2019-02-20       Impact factor: 3.984

Review 10.  Carbon monoxide in the treatment of sepsis.

Authors:  Kiichi Nakahira; Augustine M K Choi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-23       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.